Stocks · News reference
RBC Raises Price Target on Revolution Medicines
Following the company's third-quarter earnings report, RBC increased its price target for Revolution Medicines to $321 from $260 while maintaining an Outperform rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321
Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298
Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340